Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ101810200,29
KB10401041-0,38
PKN57,1557,18-0,47
Msft0,37
Nokia4,76254,7675-0,58
IBM1,32
Mercedes-Benz Group AG60,7360,76-0,61
PFE0,67
14.02.2025 9:27:51
Indexy online
AD Index online
select
AD Index online
 

  • 11.02.2025 18:02:11
Xencor (Stuttgart)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
15,90 0,00 0,00 636
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2025
Popis společnosti
Obecné informace
Název společnostiXencor Inc
TickerXNCR
Kmenové akcie:Ordinary Shares
RICXNCR.O
ISIN-
Prioritní akcieConv. Pref. Shrs Series A-1
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs
Prioritní akcieOrdinary Shares
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 280
Akcie v oběhu k 30.10.2024 69 982 030
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice465 N. HALSTEAD ST., SUITE 200
MěstoPASADENA
PSČ91107
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 263 055 900
Fax16263050350

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Xencor Inc revenues decreased 67% to $40.5M. Net loss increased 67% to $179.1M. Revenues reflect Milestone segment decrease of 99% to $500K, Royalties segment decrease from $14.5M to $0K. Higher net loss reflects Impairment on equity securities increase from $0K to $20.4M (expense), General and Adminstrative Expense increase from $12.3M to $26M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 14.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Founder and DirectorBassil Dahiyat5301.01.1997
Senior Vice President, Chief Financial OfficerBart Cornelissen4609.04.202409.04.2024
Executive Vice President - Research, Chief Scientific OfficerJohn Desjarlais59
Executive Vice President, Chief Development OfficerNancy Valente6501.05.202301.05.2023
Senior Vice President, General Counsel, Corporate SecretaryCelia Eckert5210.09.2019